Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hour continuous infusion weekly for three weeks in metastatic colorectal carcinoma

Investigational New Drugs

Volumn 16, Issue 4, 1998, Pages 341-346

  Pazdur, Richard ^a   Medgyesy, Diana C ^a   Winn, Rodger J ^a   Dakhil, S R ^b   Moore Jr , Dennis F ^b   Scalzo, Anthony ^c   Hoff, Paulo M ^a   Arbuck, Susan G ^d   Abbruzzese, James L ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^c Syracuse Hematology Oncology CCOP   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

9 AC; 9 Aminocamptothecin; Camptothecin; Colorectal cancer; Phase II

Indexed keywords

CAMPTOTHECIN DERIVATIVE; NSC 603071; UNCLASSIFIED DRUG;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; FATIGUE; FEMALE; GRANULOCYTE; GRANULOCYTOPENIA; HUMAN; HUMAN CELL; HYPOTENSION; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LEUKOPENIA; MALE; METASTASIS; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; VERTIGO; VOMITING;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 0032457859     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006248700232     Document Type: Article

References (26)

1. Gallo RC, Whang-Peng J, Adamson RH: Studies of the antitumor activity, mechanism of action and cell cycle effects of camptothecin. J Natl Cancer Inst 46: 789-795, 1971
2. Schneider E, Hsiang YH, Liu LF: DNA topoisomerases as anticancer drug targets. Adv Pharmacol 21: 149-183, 1990
3. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu FL, Silber R, Potmesil M: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046-1048, 1989
4. Gottlieb JA, Guerino AM, Call JB, Oliverio VT, Block JB: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54: 461-470, 1970
5. Gottlieb JA, Luce JK: Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 56: 103-105, 1972
6. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG: Phase II study of camptothecin in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56: 95-101, 1972
7. Rowinsky EK, Grochow LB, Hendricks GB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH, Donehower RC: Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 10: 647-656, 1992
8. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11: 909-913, 1993
9. Johnson RK, McCabe FL, Gallagher G: Comparative efficacy of topotecan, irinotecan, camptothecin, and 9-AC in preclinical tumor models. Ann Oncol 3: 85 (Suppl 1), 1992
10. Hochster H, Potmesil M, Liebes L et al.: A phase I study of 9-aminocamptothecin (9-AC) by prolonged infusion to 21 days. Ann Oncol 7: 130 (Suppl 1), 1996
11. Fassberg J, Stella VJ: A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 81: 676-684, 1992
12. Takimoto CH, Klecker RW, Dahut WL, Yee LK, Strong JM, Allegra CJ, Green JL: Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography. J Chromatogr B Biomed Appl 655: 97-104, 1994
13. Dahut W, Harold N, Takimoto C, Allegra C, Chen A, Hamilton JM, Arbuck S, Sorensen M, Grollman F, Nakashima H, Lieberman R, Liang M, Corse W, Grem J: Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol 14: 1236-1244, 1996
14. Rubin E, Wood V, Bharti A, Trites D, Lynch C, Hurwitz S, Bartel S, Levy S, Rosowsky A, Toppmeyer D: A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res 1: 269-276, 1995
15. Kraut EH, Balcerzak SP, O'Rourke M, Petrus J, Mayernik D: Phase II trial of 9-aminocamptothecin in patients with refractory breast cancer. Proc Am Soc Clin Oncol 16: 177a (Abstr 620), 1997
16. Ansari RH, Masters GA, Hoffman PC, Hoehne C, Critchlow R, Sciortino D, Kuglar JW, Ratain MJ, Golomb HM, Vokes EE: A phase II trial of 9-aminocamptothecin (9-AC) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 15: 480 (Abstr 1247), 1996
17. Potmesil M, Arbuck SG, Takimoto CH, Liebes L, Hochster H: 9-Aminocamptothecin and beyond: preclinical and clinical studies. The camptothecins: from discovery to patient. Ann NY Acad Sci 803: 231-246, 1996
18. Pazdur R, Diaz-Canton E, Ballard WP, Bradof JE, Gra-ham S, Arbuck SG, Abbruzzese JL: Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. J Clin Oncol 15: 2905-2909, 1997
19. Takimoto CH, Dahut W, Harold N, Morrison GB, Quinn MF, Cullen E, Liang MD, Arbuck SG, Chen A, Hamilton JM, Allegra CJ, Sorensen JM, Grem JL: A phase I trial of a prolonged infusion of 9-aminocamptothecin (9-AC) in adult patients with solid tumors. Proc Am Soc Clin Oncol 15: 488 (Abstr 1554), 1996
20. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH: Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8: 147-159, 1990
21. Gehan EA: The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. J Chronic Disease 13: 346-353, 1961
22. Von Hoff DD, Rothenberg ML, Pilot HC, Elfring GL, Mohrland JS, Schaaf LJ, Neff LL, Locker PK: Irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer: overall results of FDA reviewed pivotal US clinical trials. Proc Am Soc Clin Oncol 16: 228a (Abstr 803), 1997
23. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S, Gonzalez C: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14: 709-715, 1996
24. Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA 3rd, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DD: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14: 1128-1135, 1996
25. Cunningham D, Pyrhönen S, James RD, Punt CJA, Hickish TS, Heikkila R, Johannesen T, Starkhammar H, Topham CA, Ong E, Herart P, Jacques C: A phase III multicenter randomized study of CPR-11 versus supportive care (SC) alone in patients (pts) with 5-FU-resistant metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 17: 1a (Abstr 2), 1998
26. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271-291, 1993